evipedia.ai
← Back

Pycnogenol for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Pycnogenol, a French maritime pine bark supplement, is used for circulation, joint and blood sugar complaints. Mostly small, short, maker-funded trials found relief of leg heaviness and swelling, menopausal and asthma symptoms, better vision in diabetic eye damage, with further support for knee pain and diabetic blood sugar control. It is well tolerated in trials; concerns are added effects with anticlotting, blood pressure and diabetes drugs and unknown pregnancy safety. (Full Review)

Protocol

Standard dose
150 mg/day
Three divided doses; studied range 60–300 mg/day
Higher-dose approach
300 mg/day
100 mg three times daily for venous insufficiency
Time of day
With meals
Morning and evening is the common pattern for tolerance; no time-of-day effect studied
Time to effect
Venous symptoms
4–8 weeks
Leg swelling, heaviness and pain
Menopausal symptoms
4–12 weeks
Hot flashes and sleep problems
Joint symptoms
3 months
Knee osteoarthritis pain and function

Benefits

Contraindications
  • Pregnancy, especially the first trimester
  • Breastfeeding
  • Children under 6 years
  • Bleeding disorders (hemophilia or von Willebrand disease)
  • Organ transplant recipients on immunosuppressants
    •
Key Interactions
  • Calcium channel blockers (such as nifedipine)
  • ACE inhibitors (such as enalapril or lisinopril)
  • Oral glucose-lowering drugs (metformin; sulfonylureas such as glimepiride)
  • SSRIs (such as escitalopram)
  • L-arginine
    •
Theoretical (inferred from mechanism)
  • Anticoagulants and antiplatelet drugs (warfarin, aspirin)
  • Over-the-counter NSAIDs (such as ibuprofen, naproxen)
  • Immunosuppressants (such as cyclosporine, tacrolimus)
  • Antiplatelet supplements (fish oil omega-3 fatty acids, ginkgo)
  • Glucose-lowering supplements (berberine, cinnamon)
  • Blood pressure-lowering supplements (L-citrulline, beetroot nitrate)
  • Surgery and invasive procedures
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal upset, dizziness and headache; Rhabdomyolysis with excess intake
    •
  • Speculative: Bleeding when combined with drugs that slow blood clotting; Low blood glucose with glucose-lowering drugs; Immune stimulation; Unknown safety in pregnancy and lactation; Forgone benefit when replacing proven therapy
    •

Monitoring

Marker Target Why
Fasting glucose 70–99 mg/dL Expected to change; safety check on diabetes drugs
HbA1c 4.0–5.6% Expected to change in type 2 diabetes
Blood pressure <130/80 mm Hg Safety check on antihypertensives; possible small change
LDL cholesterol <100 mg/dL Expected to change slightly
hs-CRP No established target; track change from own baseline Expected to change
INR (warfarin users only) No established target for this purpose; track change from own stable values Safety check

Cadence: Baseline before starting; check at 2–4 weeks for blood pressure, glucose and INR in people on interacting drugs, then laboratory markers at 3 months, then every 6–12 months while use continues

Qualitative Assessment

  • Leg heaviness, swelling and evening ankle puffiness
  • Joint pain, stiffness and walking distance
  • Hot flashes and sleep quality in perimenopause
  • Stomach comfort, dizziness and headache after doses
  • Easy bruising, gum bleeding or nosebleeds
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.